[go: up one dir, main page]

UY39669A - Usos de anticuerpos cd79b para aplicaciones terapéuticas autoinmunitarias - Google Patents

Usos de anticuerpos cd79b para aplicaciones terapéuticas autoinmunitarias

Info

Publication number
UY39669A
UY39669A UY0001039669A UY39669A UY39669A UY 39669 A UY39669 A UY 39669A UY 0001039669 A UY0001039669 A UY 0001039669A UY 39669 A UY39669 A UY 39669A UY 39669 A UY39669 A UY 39669A
Authority
UY
Uruguay
Prior art keywords
therapeutic applications
cd79b antibodies
cd79b
autoimmune therapeutic
autoimmune
Prior art date
Application number
UY0001039669A
Other languages
English (en)
Inventor
Fang Shen
Songmao Zheng
John Emery
F Nemeth Jennifer
Pankaj Seth
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of UY39669A publication Critical patent/UY39669A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona dominios de unión que se unen a la proteína del cúmulo de diferenciación 79b (cd79b), que comprende los dominios de unión al antígeno que se unen a cd79b, polinucleótidos que los codifican, vectores, células huésped, métodos de preparación y uso de estos.
UY0001039669A 2021-03-12 2022-03-11 Usos de anticuerpos cd79b para aplicaciones terapéuticas autoinmunitarias UY39669A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163160127P 2021-03-12 2021-03-12
US202163252910P 2021-10-06 2021-10-06

Publications (1)

Publication Number Publication Date
UY39669A true UY39669A (es) 2022-09-30

Family

ID=83227107

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039669A UY39669A (es) 2021-03-12 2022-03-11 Usos de anticuerpos cd79b para aplicaciones terapéuticas autoinmunitarias

Country Status (6)

Country Link
US (1) US20240158499A1 (es)
EP (1) EP4304649A1 (es)
JP (1) JP2024510200A (es)
TW (1) TW202302648A (es)
UY (1) UY39669A (es)
WO (1) WO2022192649A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888113B1 (en) * 2005-05-27 2014-06-25 Biogen Idec MA Inc. Tweak binding antibodies
EP2310416A1 (en) * 2008-06-30 2011-04-20 Morphotek, Inc. Anti-gd2 antibodies and methods and uses related thereto
KR20170086549A (ko) * 2014-12-05 2017-07-26 제넨테크, 인크. 항-CD79b 항체 및 이용 방법
WO2020142626A1 (en) * 2019-01-04 2020-07-09 Gigagen, Inc. Anti-ox40 binding proteins and methods of use thereof
WO2020223279A1 (en) * 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. VECTORIZED ANTIBODIES (vAb) AND USES THEREOF

Also Published As

Publication number Publication date
JP2024510200A (ja) 2024-03-06
WO2022192649A1 (en) 2022-09-15
EP4304649A1 (en) 2024-01-17
US20240158499A1 (en) 2024-05-16
TW202302648A (zh) 2023-01-16

Similar Documents

Publication Publication Date Title
MX2022014938A (es) Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas.
CO2023012586A2 (es) Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas
CO2021011327A2 (es) Anticuerpos y receptores quiméricos de antígenos específicos para receptor 1 huérfano tipo receptor tirosina-cinasa (ror1)
ECSP20082991A (es) Agentes aglutinantes del psma y usos de estos
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
CO2019003809A2 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso
MX2021013161A (es) Polipeptidos que contienen dominios de union de novo y usos de los mismos.
AR103488A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
PE20211660A1 (es) Neoantigenos prostaticos y sus usos
CL2022003004A1 (es) Agentes de unión a ilt y métodos para su uso
MX2020010235A (es) Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos.
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
ECSP22015276A (es) Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos
BR112023001500A2 (pt) Proteínas que compreendem domínios de ligação ao antígeno hla-g e usos dos mesmos
CL2020001334A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos. (divisional solicitud 201900999)
AR122674A1 (es) Anticuerpos de unión a cd3 y cd19
CL2023000909A1 (es) Materiales y métodos para la unión de siglec-3/cd33 (divisional)..
AR121335A1 (es) Neoantígenos expresados en mieloma múltiple y sus usos
UY39669A (es) Usos de anticuerpos cd79b para aplicaciones terapéuticas autoinmunitarias
AR122163A1 (es) Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas
CL2022002187A1 (es) Neoantígenos expresados en el cáncer de ovario y sus usos.
AR126054A1 (es) Anticuerpos anti-ddr2 y usos de estos
AR122514A1 (es) Constructos anti-cd93 y usos de estos
AR109237A1 (es) Anticuerpos contra ip-10 y sus usos